The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Communications and UpdatesFull Access

Discrepancy in Response and Remission Rates for SAMe-Treated Patients in a Double-Blind, Randomized Clinical Trial

To the Editor: In the August 2010 issue of the Journal, George I. Papakostas, M.D., et al. (1), appear to have inadvertently made a calculation error, which has affected the results of their data. The authors stated that “response rates for SAMe-treated patients versus placebo-treated patients were 36.1% versus 17.6%, respectively, while remission rates were 25.8% versus 11.7%, respectively” (1, p. 946).

Our calculations, based on the data presented in the article, are inconsistent with the aforementioned percentages. The quoted percentage is 36.1% for SAMe plus antidepressant treatment among responders, whereas the actual number of responders indicated on page 945 is 18/39, or 46.1%. Likewise, the quoted percentage for SAMe plus antidepressant treatment among patients who remitted is 25.8%, whereas the actual number of these patients cited on page 945 is 14/39, or 35.8%. Interestingly, Figure 2 appears to correspond with our calculations rather than the percentages cited in the article. We believe that 36.1% was given instead of 46.1% and 25.8% instead of 35.8%. Furthermore, we believe the alteration in these percentages would affect the number needed to treat.

We would be grateful if the authors could clarify the results of this thought-provoking study.

Pittsburgh, PA.

The authors report no financial relationships with commercial interests.

This letter was accepted for publication in September 2010.

Reference

1. Papakostas GI , Mischoulon D , Shyu I , Alpert JE , Fava M : S-Adenosyl methionine (SAME) augmentation of serotonin reup-take inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010; 167: 942–948LinkGoogle Scholar